Sulfuric-acid supply risks for Kazakhstan uranium production Report Interpretation

Overview

This update examines how renewed sulfuric-acid supply risk could affect Kazakhstan's uranium production. Morgan Stanley concludes that a tighter acid supply backdrop is positive for uranium prices and reiterates its positive view on Kazatomprom and CGN Mining, while recognizing that higher input costs could offset part of the benefit.

Core views

Morgan Stanley highlights a new supply-side risk for Kazakhstan uranium production after Russia introduced temporary restrictions on sulfuric-acid exports from 22 September through 31 December 2026. The restrictions are intended to preserve supply for Russian industrial and fertilizer users, although exports can still occur with approval from the Prime Minister or deputies and under international transit or intergovernmental arrangements. This matters because Russia accounted for one-third of Kazakhstan's sulfuric-acid imports in 7M26. The report notes that Russian acid suppliers have confirmed their intention to fulfill existing 2026 delivery contracts to Kazakh uranium producers and are applying for export approvals. Nonetheless, the policy raises uncertainty over a key production input. The concern is compounded by the delayed commissioning of Kazatomprom's 800kt-per-year TQZ sulfuric-acid plant: the expected start has moved from 1Q27 to 3Q27–1Q28. Morgan Stanley therefore sees a risk that acid availability could constrain uranium output in Kazakhstan. The institution argues that a production constraint in this major uranium-producing region could push uranium prices higher. It notes that uranium spot and term prices had continued to trend higher even as uranium equities sold off following weak 1H26 results and US rate hikes. Morgan Stanley reiterates its positive view on Kazatomprom and CGN Mining as potential beneficiaries of higher uranium prices, but cautions that rising production costs may offset some of the positive earnings effect. For CGN Mining, Morgan Stanley values separate businesses differently: its mining operations, including offtake and trading from self-owned mines, are valued at 30x 2026e P/E, a multiple described as similar to global uranium miners; its 2.61% stake in Paladin Energy is valued at market value; and its CGN Global Uranium international trading operation is valued at acquisition value. The report identifies higher uranium prices and a faster-than-expected ramp-up at the Zhalpak Deposit as upside factors, while non-controlling interests in mine assets, geopolitical risk and weaker-than-expected uranium demand are downside risks. For Kazatomprom, Morgan Stanley states that its price target is derived using DCF. The framework uses a 10.4% WACC, a 12% cost of equity based on a 1.3 beta, a 4.2% risk-free rate and a 6.0% equity risk premium, plus a 3% perpetual revenue-growth assumption beyond the explicit forecast period. Higher uranium prices and better production-cost control are identified as upside factors, whereas weaker uranium demand and higher-than-expected production costs are downside risks.

Analysis framework

Morgan Stanley first traces the sulfuric-acid supply disruption from Russian export restrictions and Kazakhstan's import dependence, then combines this with the delayed Kazatomprom acid plant to assess potential uranium-production constraints and price effects. It applies company-specific valuation approaches to CGN Mining and Kazatomprom and identifies uranium-price, demand, cost, operational and geopolitical sensitivities.

Methodology notes

• Industry AnalysisSupply-demand framework

  Sulfuric-acid supply constraints as a potential limit on Kazakhstan uranium production.

  The report links Russian export restrictions, Kazakhstan's reliance on Russian acid imports and the delayed domestic acid plant to a possible reduction in uranium supply, which could support uranium prices.

• Valuation methodsSOTP (Sum-of-the-Parts) Valuation

  Separate valuation of CGN Mining's mining, Paladin Energy holding and international trading businesses.

  Morgan Stanley assigns a 30x 2026e P/E multiple to mining, market value to the Paladin stake and acquisition value to CGN Global Uranium, then combines these business values.

• Valuation methodsDCF (Discounted Cash Flow)

  Kazatomprom price target based on discounted future cash flows.

  The DCF discounts forecast cash flows using a 10.4% WACC and assumes 3% revenue growth after the explicit forecast period.

• Quantitative, Factor, and Portfolio TheoryBeta/alpha analysis

  Cost of equity derived from beta, the risk-free rate and the equity risk premium.

  For Kazatomprom, Morgan Stanley uses a 1.3 beta, 4.2% risk-free rate and 6.0% equity risk premium to calculate a 12% cost of equity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• CGN Mining Co Ltd (1164.HK)

  Covered uranium miner that Morgan Stanley views positively as a potential beneficiary of higher uranium prices.

  Strengths

  Exposure to mining, offtake and trading from self-owned mines; a 2.61% equity interest in Paladin Energy; and CGN Global Uranium trading operations.

  Weaknesses

  Non-controlling interests in mine assets.

  Comparison

  The 30x 2026e P/E applied to its mining business is described as similar to that of global uranium miners.

  Risks

  Geopolitical risk and weaker-than-expected uranium demand.

• Kazatomprom (KAPQ.L)

  Covered uranium producer that Morgan Stanley views positively because acid-supply constraints could support uranium prices.

  Strengths

  Potential benefit from higher uranium prices.

  Weaknesses

  The 800kt-per-year TQZ sulfuric-acid plant commissioning has been delayed to 3Q27–1Q28.

  Risks

  Weaker-than-expected uranium demand and higher-than-expected production costs.

• Paladin Energy (PDN.AU)

  CGN Mining holds a 2.61% equity interest that Morgan Stanley values at market value.

Key data

• Russian sulfuric-acid export restrictions22 September to 31 December 2026Temporary restrictions introduced to maintain supplies for Russian industrial and fertilizer producers.
• Russia share of Kazakhstan sulfuric-acid importsOne-thirdShare in 7M26.
• TQZ sulfuric-acid plant capacity800kt/yrKazatomprom plant commissioning delayed from 1Q27 to 3Q27–1Q28.
• CGN Mining mining-business valuation30x 2026e P/EApplied to mining operations including offtake and trading from self-owned mines.
• CGN Mining Paladin Energy interest2.61%Valued at market value in Morgan Stanley's framework.
• Kazatomprom DCF WACC10.4%Used in the price-target methodology.
• Kazatomprom terminal revenue growth3%Annual growth assumption beyond the explicit forecast period.

Impact & implications

Morgan Stanley believes acid shortages could restrict Kazakhstan uranium production and tighten the uranium market, supporting spot and term uranium prices. This is presented as favorable for uranium miners, particularly Kazatomprom and CGN Mining, although elevated acid and other production costs could reduce part of the benefit.

Risks

• For CGN Mining, non-controlling interests in mine assets, geopolitical risk and weaker-than-expected uranium demand are identified as downside risks.
• For Kazatomprom, weaker-than-expected uranium demand and higher-than-expected production costs are identified as downside risks.
• Higher acid and other production costs could partially offset the benefit of higher uranium prices for uranium miners.

What to watch

• Russian approvals and fulfillment of sulfuric-acid delivery contracts to Kazakh uranium producers during 2026.
• The revised 3Q27–1Q28 commissioning timeline for Kazatomprom's TQZ sulfuric-acid plant.
• Uranium spot and term-price trends, uranium demand, production costs and the Zhalpak Deposit ramp-up.